Pioglitazone: In vitro effects on rat hepatoma cells and in vivo liver hypertrophy in kkay mice

Pharmacology

Volumn 54, Issue 4, 1997, Pages 169-178

  Weinstock, R S ^a,b   Murray, F T ^c   Diani, A ^c   Sangani, G A ^a,b   Wachowski, M B ^c   Messina, J L ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b SYRACUSE VA MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

DNA synthesis; H4 cells; Insulin; KKAy mice; Liver hypertrophy; Pioglitazone

Indexed keywords

DNA; GLIBENCLAMIDE; GLUCOSE; INSULIN; PIOGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DNA SYNTHESIS; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HEPATOMA CELL; INSULIN SENSITIVITY; LIPOGENESIS; LIVER CELL; LIVER HISTOLOGY; LIVER HYPERTROPHY; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; DIABETES MELLITUS, TYPE 2; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GLYBURIDE; HYPERTROPHY; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; MALE; MICE; MICE, INBRED C57BL; ORGAN SIZE; RATS; THIAZOLES; THIAZOLIDINEDIONES; TUMOR CELLS, CULTURED;

EID: 0030978922     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139484     Document Type: Article

References (23)

1. Moller DE, Flier JS: Insulin resistance-Mechanisms, syndromes and implications. N Engl J Med 1991:325:938-948.
2. Hofmann CA, Colca JR: New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 1992;15:1075-1078.
3. Sugiyama Y. Taketomi S. Shimura Y, Ikeda H, Fujita T: Effects of pio-glitazonc on glucose and lipid metabolism in Wistar fatty rats. Arz-ncimittelforschung 1990:40:263-267.
4. Sugiyama Y, Shimura Y. Ikeda H: Effect of pioglitazone on hepat ic and peripheral insulin resistance in Wistar fatty rats. Arzneimittelforsehung 1990:40:436-440.
5. Ikeda H. Taketomi S. Sugiyama Y. Shimura Y. Sohda T. Meguro K. Fujita T: Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arz-ncimittelforschung 1990;40:156-162.
6. Klelzicn RF. Foellmi LA. Harris PK. Wyse BM. Clarke SD: Adipocyte fatty acid-binding protein: Regulation of gene expression in vivo and in vitro by an insulin sensitizing agent. Mol Pharmacol 1992:42: 558-562.
7. Kcmnitz JW, Elson DF, Roecker EB. Baum ST. Bergman RN. Mc-glasson MD: Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin and lipid levels, and lowers blood pressure in obese insulin-resistant rhesus monkeys. Diabetes 1994:43:204-211.
8. Hofmann C, Lorenz K, Colca JR: Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihypcrgly-ecmic agent pioglitazone. Endocrinology 1991:129:1915-1925.
9. Saha AK. Kurowski TG. Colca JR. Ruderman NB: Lipid abnormalities in tissues of the KK. V mouse: Effects of pioglitazone on malonyl CoA and diacylglycérol. Am J Physiol 1994;267:E95-E 101.
10. Malaise WJ. Lebrun P: Mechanisms of sulfonylurea-induced insulin release. Diabetes Care 1990:12(suppl 3):9-17.
11. Kobayashi M. Iwanishi M. Egawa K, Shigeta Y: Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 1992;41:476-483.
12. Hayakawa T, Shiraki T, Morimoto T. Sliii K. Ikeda H: Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats. Biochem Biophys Res Commun 1996:223:439-444.
13. Sandouk T. Reda D, Hofmann C: Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells. Am J Physiol 1993;264:C1600-C1608.
14. Hofmann CA. Edwards CW III. Hillman RM, Colca JR: Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: Evaluation of liver GLUT2 and phosphoenolpyruvate carboxyki-nase expression. Endocrinology 1992:130:735-740.
15. Hofmann C, Lorenz K. Williams D, Palazuk B.I. Colca JR: Insulin sensitization in diabetic rat liver by an antihypcrglycemic agent. Metabolism 1995:44:384-389.
16. Messina JL, McCann JA: Interaction of insulin and phorbol esters on the regulation of DNA synthesis in rat hepatoma cells. Biochem Biophys Res Commun i990:172:759-766.
17. Ohtani K. Shimizu II, Tanaka Y, Sato N, Mori M: Pioglitazone hydrochloride stimulates insulin secretion in HIT-T 15 cells by inducing Ca2+ influx. J Endocrinol 1996:150: 107-111.
18. Iwatsuka H. Shino A, Suzuoki Z: General survey of diabetic features of yellow KK mice. Endocrinol Jpn 1970:17:23-35.
19. Lehmann JM. Moore LB. Smith-Oliver TA, Wilkison WO, Wilson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activatcd receptor y (PPARy). J Biol Chem 1995:270:12953-12956.
20. Vidal-Puig A, Jimencz-Linan M, Lowell BB, Hamann A, Hu E, Spie-gclman B. Flier JS, Moller DE: Regulation of PPARy gene expression by nutrition and obesity in rodents. J Clin Invest 1996:97:2553-2561.
21. Castle CK. Colca JR. Melchior GW: Lipoprotein profile characterization of the KKA> mouse, a rodent model of type II diabetes mcllitus. before and after treatment with the insulin-sensitizing agent pioglitazone. Ar-terioscler Thromb 1993; 13:302-309.
22. Sutter SL. Nolan JJ. Wallace P, Gumbner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in N1DDM subjects. DiabetesCarc 1992:15:193-203.
23. Iwamoto Y. Kazuyat: A new oral antidiabetic agent. CS-045. Sougou-Rynshov 1990:39:2053-2057.